artículo.page.titleprefix
Meningococcal burden of disease in Argentina: 10 years epidemiologic review

dc.creatorNeyro, Silvina
dc.creatorUrueña, Analía
dc.creatorEfron, Adriana
dc.creatorRancaño, Carolina
dc.creatorPannunzio, Maria E.
dc.creatorSeoane, Maria B.
dc.creatorGomez, Jorge A.
dc.creatorGiglio, Norberto
dc.date.accessioned2025-11-20T15:12:17Z
dc.date.available2025-11-20T15:12:17Z
dc.date.issued2023
dc.descriptionFil: Urueña, Analia. Centro de Estudios para la Prevención y Control de Enfermedades Transmisibles CEPYCET, Universidad ISALUD.
dc.description.abstractInvasive meningococcal disease (IMD) is an uncommon but serious and potentially fatal condition, mainly affecting infants. In 2017, Argentina introduced a vaccination program against serogroups A, C, W and Y (MenACWY) for infants aged 3, 5 and 15 months and adolescents aged 11 years. The objective of this study was to review the burden of IMD in Argentina in 2010–2019. Data were obtained from national surveillance databases, and the study estimated IMD incidence, mortality, case-fatality rates, and serogroup distributions across age groups. A total of 1,972 IMD cases were reported in the study period, with the highest incidence in infants aged < 1 year. Incidence peaked in 2013 and subsequently declined. Mortality rates were 18 times higher in infants than in other age groups, reflecting the high impact of IMD in this age group. The case-fatality rate was 8.5% on average and increased with age. The proportion of notified cases with serogroup identification increased over the period, reaching 91% in 2019. The most common serogroups over the study period were serogroup B (48%) and serogroup W (42%), with an increase in B relative to W since 2015. In infants aged < 1 year, the proportion of serogroup B increased in recent years, reaching around 70% of characterized cases in 2018–2019. These results show the dynamism of IMD and indicate the importance of vaccination at an early age and offering protection against predominant serogroups. These data are valuable to support evidence-based decision-making in healthcare.en_US
dc.identifier.citationNeyro S, Urueña A, Efron A, Rancaño C, Pannunzio ME, Seoane MB, et al. Meningococcal burden of disease in Argentina: 10 years epidemiologic review. Hum Vaccin Immunother. 2023;19(2). doi: https://10.1080/21645515.2023.2237391en_US
dc.identifier.doihttps://doi.org/10.1080/21645515.2023.2237391
dc.identifier.issn2164-5515
dc.identifier.urihttps://www.tandfonline.com/doi/pdf/10.1080/21645515.2023.2237391?needAccess=true&role=button
dc.identifier.urihttp://rid.isalud.edu.ar/handle/1/2983
dc.journal.issue2
dc.journal.volume19
dc.language.isoenen_AR
dc.rightsCC BY-NC-ND 4.0
dc.sourceHuman Vaccines & Inmunotherapeutics, 19(2)
dc.subjectCHILDRENen_US
dc.subjectDISEASE BURDENen_US
dc.subjectMENINGOCOCCAL DISEASEen_US
dc.subjectSEROGROUPSen_US
dc.subjectNIÑOSes_AR
dc.subjectNIÑASes_AR
dc.subjectCARGA DE MORBILIDADes_AR
dc.subjectINFECCIONES MENINGOCÓCICASes_AR
dc.subjectSEROGRUPOSes_AR
dc.titleMeningococcal burden of disease in Argentina: 10 years epidemiologic reviewen_US
dc.title.journalHuman Vaccines & Inmunotherapeutics
dc.typeArtículoes_AR
dc.typeinfo:ar-repo/semantics/artículoes_AR
dc.typeinfo:eu-repo/semantics/articlees_AR
dspace.entity.typeARTÍCULO

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Human_Vaccines_2023_19_Urueña.pdf
Size:
3.93 MB
Format:
Adobe Portable Document Format